LONGEVA.

SLU-PP-332: limits of adverse-event evidence

Billon and colleagues studied SLU-PP-332 in a muscle cell line and in mice. The inspected 2023 abstract describes cellular respiration and exercise endurance; it gives no patient adverse-event frequencies. [1]

This preclinical study does not establish a clinical adverse-reaction profile or human safety for SLU-PP-332. Its model findings also do not establish safety of a particular reagent batch. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Patient adverse-event frequenciesMuscle cell culture and miceThe abstract describes cellular respiration and exercise endurance and gives no patient adverse-event frequencies; this preclinical study does not establish a clinical adverse-reaction profile in humans[1]

References

  1. Billon C et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity https://doi.org/10.1021/acschembio.2c00720.